The reported statements, read against the company's own industry.
Financials view
Market Capitalization
572.56MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Revenue (TTM)
320.35MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Profit Margin
-23.04%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Beta
0.8880x
vs all stocks
Updated Jul 18, 2026
52-Week Change
13.58%
vs all stocks
Updated Jul 18, 2026
Market Capitalization
572.56MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Enterprise Value
324.91MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Forward P/E
-13.45x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Price to Sales (TTM)
1.82x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Price to Book (MRQ)
0.5648x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Enterprise to Revenue
1.01x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Enterprise to EBITDA
-4.21x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Gross Margin
30.21%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 38.71%.Updated Jul 18, 2026
Profit Margin
-23.04%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Operating Margin
-45.01%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Return on Assets (TTM)
-5.37%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Return on Equity (TTM)
-6.92%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Revenue (TTM)
320.35MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Revenue per Share (TTM)
10.40USDUpdated Jul 18, 2026
Quarterly Revenue Growth
-3.20%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Gross Profit (TTM)
124.02MUSD
vs all stocks (USD)
Updated Jul 18, 2026
EBITDA (TTM)
-77.19MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Net Income (TTM)
-73.81MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Quarterly Earnings Growth (YoY)
-3.16%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Operating Cash Flow (TTM)
-90.11MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Levered Free Cash Flow (TTM)
-105.94MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Jul 18, 2026
Payout Ratio
0.00%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Minority Interest (Equity)
-5.27MUSDFY2025 · Dec 31, 2025
Revenue
322.67MUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
191.80MUSDFY2025 · Dec 31, 2025
Gross Profit
130.88MUSDFY2025 · Dec 31, 2025
Operating Income
-91.10MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-70.03MUSDFY2025 · Dec 31, 2025
Income Tax Expense
-8.39MUSDFY2025 · Dec 31, 2025
Net Income
-61.63MUSDFY2025 · Dec 31, 2025
EBIT
-69.95MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-35.90MUSDFY2025 · Dec 31, 2025
Research & Development
53.91MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
160.03MUSDFY2025 · Dec 31, 2025
Non-operating Interest Income
30.92MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
75.00KUSDFY2025 · Dec 31, 2025
EPS (Basic)
-1.97USDFY2025 · Dec 31, 2025
EPS (Diluted)
-1.97USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
30.78MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
30.78MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-61.63MUSDFY2025 · Dec 31, 2025
Minority Interests (P&L)
1.12MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
-122.95MUSDFY2025 · Dec 31, 2025
Free Cash Flow
-145.52MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
50.33MUSDFY2025 · Dec 31, 2025
Income Tax Paid
96.44MUSDFY2025 · Dec 31, 2025
Interest Paid
52.00KUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-61.63MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
24.12MUSDFY2025 · Dec 31, 2025
Deferred Taxes (CF)
-278.00KUSDFY2025 · Dec 31, 2025
Stock-based Compensation
39.58MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
1.79MUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-23.25MUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
550.00KUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-103.84MUSDFY2025 · Dec 31, 2025
Capital Expenditures
-22.57MUSDFY2025 · Dec 31, 2025
Net Acquisitions
3.77MUSDFY2025 · Dec 31, 2025
Purchase of Investments
-80.84MUSDFY2025 · Dec 31, 2025
Sale of Investments
211.01MUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
111.37MUSDFY2025 · Dec 31, 2025
Long-term Debt Payments
-870.00KUSDFY2025 · Dec 31, 2025
Net Short-term Debt Issuance
-471.00KUSDFY2025 · Dec 31, 2025
Common Stock Repurchase
-13.92MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
-15.26MUSDFY2025 · Dec 31, 2025
Shares Outstanding
28.85MSharesUpdated Jul 18, 2026
Float Shares
17.56MSharesUpdated Jul 18, 2026
Shares Short
2.63MSharesUpdated Jul 18, 2026
Short Ratio
6.94days
vs all stocks
Updated Jul 18, 2026
Short % of Shares Outstanding
14.58%
vs all stocks
Provider-reported. Shares Short ÷ Shares Outstanding on this page gives 9.11%.Updated Jul 18, 2026
% Held by Insiders
36.66%
vs all stocks
Updated Jul 18, 2026
% Held by Institutions
63.41%
vs all stocks
Updated Jul 18, 2026
Total Cash (MRQ)
276.30MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Total Cash per Share (MRQ)
9.73USDUpdated Jul 18, 2026
Total Debt (MRQ)
10.17MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Total Debt to Equity (MRQ)
0.0097x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Current Ratio (MRQ)
5.32x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Book Value per Share (MRQ)
36.39USDUpdated Jul 18, 2026
Total Assets
1.21BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
550.49MUSDFY2025 · Dec 31, 2025
Total Liabilities
106.81MUSDFY2025 · Dec 31, 2025
Total Non-current Assets
663.03MUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
21.84MUSDFY2025 · Dec 31, 2025
Total Current Liabilities
84.97MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
50.19MUSDFY2025 · Dec 31, 2025
Other Short-term Investments
285.88MUSDFY2025 · Dec 31, 2025
Accounts Receivable
84.76MUSDFY2025 · Dec 31, 2025
Inventory
10.60MUSDFY2025 · Dec 31, 2025
Accounts Payable
18.65MUSDFY2025 · Dec 31, 2025
Short-term Debt
1.94MUSDFY2025 · Dec 31, 2025
Deferred Revenue
31.78MUSDFY2025 · Dec 31, 2025
Long-term Debt
5.74MUSDFY2025 · Dec 31, 2025
Other Non-current Liabilities
9.17MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
3.00KUSDFY2025 · Dec 31, 2025
Retained Earnings
529.95MUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.11BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
13.46USDUpdated Jul 18, 2026
52-Week High
31.04USDUpdated Jul 18, 2026
52-Week Change
13.58%
vs all stocks
Updated Jul 18, 2026
Beta
0.8880x
vs all stocks
Updated Jul 18, 2026
50-Day MA
18.25USDUpdated Jul 18, 2026
200-Day MA
21.55USDUpdated Jul 18, 2026
Avg 10-Day Volume
219.36KSharesUpdated Jul 18, 2026
Avg 30-Day Volume
306.51KSharesUpdated Jul 18, 2026
Diluted EPS (TTM)
-2.40USDUpdated Jul 18, 2026
Other Income / Expense
-9.77MUSDFY2025 · Dec 31, 2025
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How is this stock valued?
Inverted P/B With Liquidity And Equity Ratio
It trades below book value, with current assets ample and the balance sheet equity-funded.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -45%, lower than 95% of its Diagnostics & Research peers (median 5%)Significant